AAAAAA
Results: 26-49/49
Authors:
Kuehn, T
Klauss, W
Darsow, M
Regele, S
Flock, F
Maiterth, C
Dahlbender, R
Wendt, I
Kreienberg, R
Citation: T. Kuehn et al., Long-term morbidity following axillary dissection in breast cancer patients - clinical assessment, significance for life quality and the impact of demographic, oncologic and therapeutic factors, BREAST CANC, 64(3), 2000, pp. 275-286
Authors:
Grab, D
Flock, F
Stohr, I
Nussle, K
Rieber, A
Fenchel, S
Brambs, HJ
Reske, SN
Kreienberg, R
Citation: D. Grab et al., Classification of asymptomatic adnexal masses by ultrasound, magnetic resonance imaging, and positron emission tomography, GYNECOL ONC, 77(3), 2000, pp. 454-459
Authors:
Flock, F
Grab, D
Pohlandt, F
Kreienberg, R
Lindner, W
Citation: F. Flock et al., Maternal and perinatal outcome after preterm premature rupture of the membranes (PPROM) before 25 weeks' gestation, GEBURTSH FR, 60(5), 2000, pp. 257-263
Authors:
Grab, D
Flock, F
Stohr, I
Rieber, A
Nussle, S
Brambs, HJ
Fenchel, S
Reske, SN
Kreienberg, R
Citation: D. Grab et al., Premenopausal adnex masses: Diagnostic accuracy of sonography, magnetic resonance imaging, and positron emission tomography, GEBURTSH FR, 60(11), 2000, pp. 544-552
Authors:
Rothfuss, A
Schutz, P
Bochum, S
Volm, T
Eberhardt, E
Kreienberg, R
Vogel, W
Speit, G
Citation: A. Rothfuss et al., Induced micronucleus frequencies in peripheral lymphocytes as a screening test for carriers of a BRCA1 mutation in breast cancer families, CANCER RES, 60(2), 2000, pp. 390-394
Authors:
Vogl, FD
Frey, M
Kreienberg, R
Runnebaum, IB
Citation: Fd. Vogl et al., Autoimmunity against p53 predicts invasive cancer with poor survival in patients with an ovarian mass, BR J CANC, 83(10), 2000, pp. 1338-1343
Authors:
Fenchel, S
Kotzerke, J
Stohr, I
Grab, D
Nussle, K
Rieber, A
Kreienberg, R
Brambs, HJ
Reske, SN
Citation: S. Fenchel et al., Preoperative assessment of asymptomatic adnexal masses by positron emission tomography and F-18-fluorodeoxyglucose, NUKLEARMED, 38(4), 1999, pp. 101-107
Authors:
Rieber, A
Nussle, K
Merkle, E
Kreienberg, R
Tomczak, R
Brambs, HJ
Citation: A. Rieber et al., MR mammography: influence of menstrual cycle on the dynamic contrast enhancement of fibrocystic disease, EUR RADIOL, 9(6), 1999, pp. 1107-1112
Authors:
Schirrmeister, H
Guhlmann, A
Kotzerke, J
Santjohanser, C
Kuhn, T
Kreienberg, R
Messer, P
Nussle, K
Elsner, K
Glatting, G
Trager, H
Neumaier, B
Diederichs, C
Reske, SN
Citation: H. Schirrmeister et al., Early detection and accurate description of extent of metastatic bone disease in breast cancer with fluoride ion and positron emission tomography, J CL ONCOL, 17(8), 1999, pp. 2381-2389
Authors:
Wen, WH
Reles, A
Runnebaum, IB
Sullivan-Halley, J
Bernstein, L
Jones, LA
Felix, JC
Kreienberg, R
El-Naggar, A
Press, MF
Citation: Wh. Wen et al., p53 mutations and expression in ovarian cancers: Correlation with overall survival, INT J GYN P, 18(1), 1999, pp. 29-41
Authors:
Vogl, FD
Stickeler, E
Weyermann, M
Kohler, T
Grill, HJ
Negri, G
Kreienberg, R
Runnebaum, IB
Citation: Fd. Vogl et al., p53 autoantibodies in patients with primary ovarian cancer are associated with higher age, advanced stage and a higher proportion of p53-positive tumor cells, ONCOL-BASEL, 57(4), 1999, pp. 324-329
Authors:
Hoffken, K
Diehl, V
Kanz, L
Possinger, K
Zander, A
Kreienberg, R
Bender, HG
Elling, D
Jackisch, C
Luck, HJ
Mobus, V
Nitz, U
Thomssen, C
Untch, M
Gaisser, A
Citation: K. Hoffken et al., High dose treatment of mammary carcinoma. "Wait and see" is the reaction to the results of the randomized studies presented at the ASCO 1999 in Atlanta, GYNAKOLOGE, 32(8), 1999, pp. 655-655
Authors:
Volm, T
Mobus, V
Pfaff, P
Kreienberg, R
Citation: T. Volm et al., Infections under chemotherapy, GYNAKOLOGE, 32(7), 1999, pp. 529-539
Authors:
Kreienberg, R
Beck, L
Citation: R. Kreienberg et L. Beck, Carcinoma of the cervix - Cooperation between all partners involved as thekey to success, GYNAKOLOGE, 32(4), 1999, pp. 245-246
Authors:
Kreienberg, R
Citation: R. Kreienberg, Advanced stages of invasive carcinoma of the cervix - Operative therapy, GYNAKOLOGE, 32(4), 1999, pp. 280-290
Authors:
Mobus, V
Kreienberg, R
Citation: V. Mobus et R. Kreienberg, Systemic therapy for carcinoma of the cervix, GYNAKOLOGE, 32(4), 1999, pp. 322-328
Authors:
Regele, S
Vogl, FD
Runnebaum, IB
Kreienberg, R
Bohm, W
Citation: S. Regele et al., Malignant hemangiopericytoma of the uterus - A case report, GEBURTSH FR, 59(6), 1999, pp. 293-295
Authors:
Kuhn, T
Santjohanser, C
Koretz, K
Bohm, W
Kreienberg, R
Citation: T. Kuhn et al., Sentinel node biopsy in breast cancer patients using blue dye guided lymphography, GEBURTSH FR, 59(4), 1999, pp. 142-149
Authors:
Regele, S
Kohlberger, P
Vogl, FD
Bohm, W
Kreienberg, R
Runnebaum, IB
Citation: S. Regele et al., Sevum p53 autoantibodies in patients with minimal lesions of ductal carcinoma in situ of the breast, BR J CANC, 81(4), 1999, pp. 702-704
Authors:
Wang-Gohrke, S
Weikel, W
Risch, H
Vesprini, D
Abrahamson, J
Lerman, C
Godwin, A
Moslehi, R
Olipade, O
Brunet, JS
Stickeler, E
Kieback, DG
Kreienberg, R
Weber, B
Narod, SA
Runnebaum, IB
Citation: S. Wang-gohrke et al., Intron variants of the p53 gene are associated with increased risk for ovarian cancer but not in carriers of BRCA1 or BRCA2 germline mutations, BR J CANC, 81(1), 1999, pp. 179-183
Authors:
Volm, T
Mobus, V
Kreienberg, R
Citation: T. Volm et al., New aromatase inhibitors, ONKOLOGIE, 21(6), 1998, pp. 460-466
Authors:
Kreienberg, R
Freund, M
Citation: R. Kreienberg et M. Freund, Clinical outcome of topotecan: New strategies play an important role in the treatment of lung cancer, other solid tumors, and hemoblastosis, ONKOLOGIE, 21, 1998, pp. 1-1
Authors:
Mobus, V
Pfaff, PN
Kreienberg, R
Citation: V. Mobus et al., Topotecan (Hycamtin) in the therapy of recurrent ovarian carcinoma, ONKOLOGIE, 21, 1998, pp. 2-5
Authors:
Schumann, S
Oettling, G
Bohm, W
Kreienberg, R
Citation: S. Schumann et al., Large pelvic mass and ascites complicating pregnancy with Gorlin-Goltz-syndrome, GEBURTSH FR, 58(12), 1998, pp. 654-657